This study by the Samsung group, Korea, reported clinical outcomes of 27 patients with inoperable early stage NSCLC treated by protons to a total dose of 64 GyRBE in 8 fractions. With a median follow-up of 28.9 months, 13 (48.1%) patients experienced disease progression, including local progression in 7. Two-year LC were 73.5%, 85.7% for T1, and 61.4% for T2-3. The two-year OS was 76.5%. Grade 3 toxicities were observed in 2 (7.4%) patients. The authors concluded that hypofractionated PBT was a safe treatment option for inoperable early stage NSCLC with small tumor volumes, local control for larger tumors required further improvement.